Coinsurance Liability for High-Cost Biologic Infusions

Coinsurance on high-cost biologic infusions is not a copay problem. When a patient owes 20% of a high-cost Remicade or Ocrevus infusion, the practice is chasing a substantial balance, not a negligible one, and that changes everything about how the account has to be managed, from the first benefits check to the last collections call.

How plan design tier structure determines patient exposure

Most commercial plans sort prescription drugs into tiers, and specialty biologics almost always land on Tier 4, the tier with the steepest cost-sharing in the whole design. According to the Mployer Employee Benefit Plan Design Study, which covers more than 50,000 employer plans, the average Tier 4 copay is $123. That number sounds manageable until you notice the other figure buried in the same study: 31% of plans don't use a flat copay on Tier 4. They use coinsurance.

That 31% is the group infusion practices need to watch closely. A flat copay is predictable. Coinsurance is a percentage of a claim that can run into five figures, and on a drug like this, that percentage can push a patient close to, or straight through, their annual out-of-pocket maximum in a single visit.

For 2026, the ACA caps in-network out-of-pocket spending at $10,600 for an individual and $21,200 for a family, on non-grandfathered plans. Those numbers are ceilings that don't protect against the first hit. A patient starting biologic therapy in January can reach that ceiling in month one, and the cap only applies to in-network, covered care. Step outside the network, intentionally or by accident of scheduling, and the exposure has no ceiling.

Medicare patients face a different shape of risk. Part B coinsurance runs 20% after a $257 annual deductible, and the medical benefit side carries no legislated out-of-pocket maximum comparable to Part D. Part D looks better on paper: the IRA capped Medicare drug out-of-pocket spending at $2,000 a year starting in January 2025, with the number rising to $2,100 for 2026. But biologic infusions administered in a clinical setting are billed under Part B, not Part D, so that protection often doesn't apply to the population infusion centers treat.

A patient's real payment obligation in month one of therapy is often unknowable without a benefits check that captures deductible status, OOP accumulation to date, and whether the plan uses coinsurance or a flat copay on that tier. Guessing gets expensive, for the practice and the patient both.

Why patient liability at this scale produces a collections problem

A $2,000 to $6,000 balance doesn't behave like a normal patient receivable. Most patients don't have that kind of cash sitting around for a single office visit, and unlike a $200 copay that eventually gets paid off in installments, a bill this size tends to just sit, unpaid, aging toward write-off.

Context matters here. Specialty drugs account for more than 55% of total drug spending in one country. drug spending, even though fewer than 2% of patients use them. That's a small, concentrated population, and infusion centers sit right in the middle of it. CareRoute put the average annual cost of a specialty drug above $100,000 in 2025. Multiply that by a handful of recurring patients, and the patient-responsibility exposure on the books at any given time becomes a real number.

For buy-and-bill practices, the risk cuts deeper than a normal unpaid invoice. The practice has already bought the drug and infused it before the patient's share is ever collected. An uncollected balance directly erodes the money already spent acquiring that drug, not merely an administrative loose end.

A second cost hides behind the first one: patients who can't pay their share often stop showing up, and treatment abandonment doesn't just create a bad debt, it kills the recurring revenue that was supposed to follow every 6 to 8 weeks for the re... Patients who can't pay their share often stop showing up. Treatment abandonment doesn't just create a bad debt, it kills the recurring revenue that was supposed to follow every 6 to 8 weeks for the rest of the year. The collections issue and the retention issue are the same underlying problem: patients who don't pay stop showing up, which cuts off both the payment and the recurring revenue.

Copay assistance programs: how they work and what the practice has to manage

Assistance exists, and a fair amount of it. AmeriPharma Infusion Center reports having secured more than $55 million in patient financial assistance, which says two things at once: the money is out there, and getting it requires real, sustained operational effort.

Three kinds of programs cover this space, and they don't overlap much:

Manufacturer copay assistance, tied to a specific brand drug. Think Privigen Connect, CSL Behring's programs, Takeda Patient Support, AbbVie's patient assistance program, or Janssen CarePath. These only work for commercially insured patients. Medicare beneficiaries are excluded from manufacturer copay programs by federal law, full stop. Independent charitable foundations, like the Patient Access Network Foundation, HealthWell Foundation, or the Infusion Access Foundation. These run on income and diagnosis criteria, with eligibility thresholds that vary by foundation and diagnosis. Patient Assistance Programs (PAPs), aimed at uninsured or underinsured patients with limited income, offering free or reduced-cost medication directly from the manufacturer.

None of these replace insurance. They ride alongside it. Coordination of benefits has to be sequenced correctly, or the claim itself becomes a compliance problem, not just a payment one.

Then there's the accumulator and maximizer wrinkle. Some payers run programs that take the manufacturer's copay assistance and simply don't count it toward the patient's deductible or out-of-pocket max. The patient burns through the copay card, thinks they're covered, and then hits full liability again mid-year when the card runs dry. It's a nasty surprise, and it lands on the practice's collections desk when it happens.

Biosimilars complicate the picture further. A manufacturer copay card for a brand biologic, Humira for example, doesn't transfer to an adalimumab biosimilar. If a payer moves that biosimilar into preferred formulary position (and many are doing exactly that), the patient can lose their assistance vehicle at the exact moment they're forced to switch drugs.

None of this runs itself. Figuring out which program applies to which patient, checking eligibility, getting them enrolled, and tracking how much fund balance is left, that's dedicated intake work, and it has to start before the first infusion, not after the remit shows up short.

How biosimilar formulary dynamics and IRA price changes complicate coinsurance calculations

As of 2026, there are eight or more Humira biosimilars on the market, several for Remicade, and biosimilars now exist for Herceptin and Avastin too. The Crohn's disease biologic cost guide shows some adalimumab biosimilars price 30% to 50% below Humira's list price. That's real savings potential, but it also means a payer's preferred drug on a given tier can change under a practice's feet with little warning.

When an insurer moves a biosimilar into preferred position, the brand drug often gets bumped to non-preferred, or dropped from the formulary. That single decision can change a patient's coinsurance tier and torpedo their copay assistance eligibility in the same stroke.

The IRA adds another moving part. An SEC filing shows CMS's negotiated prices for the first 10 Part D drugs took effect in 2026, with reductions ranging from 38% to 79% off 2023 list prices, an average cut of 59.4%. The IRA pipeline extends well beyond the first round, with additional drugs across both Part B and Part D scheduled for negotiated pricing in subsequent years.

For buy-and-bill practices, Medicare reimbursement is calculated off ASP, which is itself built from list prices the IRA is actively squeezing. When a negotiated price kicks in for a drug the practice is purchasing and billing, the spread between what the drug cost to acquire and what Medicare pays back can shift, sometimes significantly.

That shift ripples straight into the patient's coinsurance math. When the allowed amount on a claim changes, whether from an ASP adjustment or a formulary reshuffle following biosimilar entry, the patient's 20% share changes right along with it. A benefits verification run at the start of therapy can be flat wrong by the second or third infusion cycle. Coinsurance liability, in other words, isn't a number you calculate once and file away. It needs rechecking, especially around plan-year changes and whenever a payer updates its formulary mid-cycle.

What benefits verification must capture to quantify coinsurance liability

Everything starts with one basic question: is this drug billed through the medical benefit or the pharmacy benefit? The same biologic can travel through either channel depending on the plan, and the cost-sharing structure attached to each is entirely different. Get this wrong at intake, and every number that follows is built on sand.

Once the channel is confirmed, a proper verification needs to pull:

• Whether the plan uses coinsurance or a flat copay, and at what rate
• Deductible status: how much has accumulated against the plan-year total, since a patient who hasn't touched their deductible yet owes far more in month one than in month seven
• Out-of-pocket max accumulation: near the max, the practice's collection exposure shrinks toward zero; at zero, it's wide open
• In-network status for both the infusion site and the prescriber, since out-of-network exposure has no cap
• Site-of-care rules: some payers require redirection to a lower-cost setting before they'll cover a service at all
• Prior authorization status and scope, matched against the actual planned drug, dose, frequency, and site
• Copay assistance eligibility, which hinges heavily on whether the patient carries commercial or Medicare coverage
• Whether an accumulator or maximizer program is in play, since that determines if manufacturer assistance counts toward the OOP max at all

Experian Health's 2025 State of Claims data found that 26% of respondents traced at least one in ten denials back to intake errors, such as wrong policy numbers or outdated insurance cards. Those are the kind of small, avoidable mistakes that corrupt a coinsurance estimate before anyone even runs the math. They're the kind of small, avoidable mistakes that corrupt a coinsurance estimate before anyone even runs the math.

Verification also has to be drug-specific. The same person's coinsurance obligation for Stelara versus an adalimumab biosimilar can differ by a wide margin, purely based on where each drug sits on the formulary. And because infusion therapy repeats on a recurring dosing schedule, a single verification at intake isn't enough. Reverification needs to happen at plan-year renewal and at every new authorization cycle, or the numbers quietly go stale.

How prior authorization gaps create compounding coinsurance liability risk

A service delivered after an authorization has expired gets treated exactly like a service delivered with no authorization at all: full denial. It doesn't matter what coinsurance estimate the practice handed the patient beforehand. The estimate becomes meaningless the moment the claim bounces.

The overhead here is not small. Specialty drug and buy-and-bill prior auth processing typically takes one to three weeks, and providers spend close to two business days a week on authorization tasks alone. For therapy that repeats on a dosing cycle, tied to specific intervals or response checkpoints, even a short approval delay throws off scheduling and makes that cycle's coinsurance estimate unreliable.

When a denial hits after treatment has already happened, the fallout is worse than an accounting adjustment. The patient agreed to treatment expecting a specific coinsurance share. The denial can shift that liability to full billed charges, and now the practice is explaining a much bigger bill to a patient who budgeted for a much smaller one. That's a communication problem and a collections problem, both rooted in an authorization failure that happened weeks earlier.

Step therapy denials add another layer. If a payer requires documented proof that a cheaper drug failed first, and the claim gets denied for skipping that step, the copay assistance program tied to the intended biologic often can't be applied either. One denial takes out two revenue supports at once.

Prior authorization denials climbed to around 31% in 2026, with much of that growth concentrated in high-complexity specialty infusion and biologic therapy. That denial rate is basically a leading indicator: it tells you how often coinsurance estimates are going to fall apart mid-cycle.

HB 3812, effective September 1, 2026, tightened the state's gold-carding rules in Texas: providers now need at least five prior submissions for a specific service and a 90% approval rate over a full year to ea... HB 3812, effective September 1, 2026, tightened the state's gold-carding rules: providers now need at least five prior submissions for a specific service and a 90% approval rate over a full year to earn a PA exemption on that service. Practices with strong approval histories on particular biologics have real reason to track that eligibility by service category, since it directly reduces future authorization risk.

Appeals overturn most denials, since available data shows that more than 80% of prior authorization appeals to Medicare Advantage plans eventually get overturned, and the AMA puts the figure at nearly 82% when denials are traced to administrative errors. denial traces back to an administrative error. Yet only about 20% of physicians consistently appeal. That gap means most of these compounding coinsurance disruptions never get contested. They just get written off, or pushed onto the patient.

What a practice's operating model needs to manage this liability at scale

Control over coinsurance liability doesn't start when the remit lands. It starts at scheduling. By the time a claim gets submitted, the patient-liability estimate has already been set or missed, the prior auth has already been confirmed or lapsed, and the copay assistance enrollment has already happened or hasn't. Everything downstream just plays out what was, or wasn't, done upfront.

A workable pre-treatment sequence covers four things:

• Benefits verification with drug-specific coinsurance capture, current OOP accumulation, and an accumulator/maximizer check
• Prior auth confirmation, with the approved scope checked directly against the planned drug, dose, frequency, and site
• Copay assistance enrollment finished before the first treatment date, not after
• Financial counseling with the patient, backed by a documented coinsurance estimate and whatever assistance offset applies

Authorization tracking needs to run as a standing report, sorted by days remaining until expiration and dollar value at risk for each patient. Reauthorization for ongoing therapy should kick off at least two weeks before the current approval runs out, not after it lapses. And denial patterns deserve regular review by payer and root cause. Denial rates in the 20% to 35% range aren't unusual in this space, so they're not surprises either. They're a known cost of doing business here, and the only real defense is catching the pattern early enough to fix what's fixable before the next infusion cycle starts.